
Michael Snyder
Articles
-
3 weeks ago |
nature.com | Chiara Herzog |Kejun Ying |Raghav Sehgal |Waylon J. Hastings |Alexander Tyshkovskiy |Sara Hägg | +19 more
On 1–2 November 2024, the annual Biomarkers of Aging conference welcomed academic and industry scientists, and partners from governmental and nongovernmental organizations, to Harvard Medical School in Boston, USA, to discuss new insights into measuring and monitoring human aging, with the aim of clinical translation. In this Meeting Report, we summarize the conference and offer potential future directions for the Biomarkers of Aging Consortium and the longevity science community at large.
-
2 months ago |
nature.com | Michael Snyder |Hayan Lee |Annika K Weimer |Aaron M Horning |Edward D. Esplin |Kristina Ayers Paul | +4 more
Correction to: Nature Cancer https://doi.org/10.1038/s43018-024-00823-z, published online 30 October 2024. In the version of the article initially published, a technique described as “intact Micro-C” should have been called “MNase-digested Intact Hi-C” and has now been corrected throughout the article.
-
Sep 15, 2024 |
nature.com | Jesse R. Poganik |Daniel Belsky |Joe LaCroix |Alan Cohen |Steven R. Cummings |Luigi Ferrucci | +15 more
AbstractBiomarkers of aging (BOA) are quantitative parameters that predict biological age and ideally its changes in response to interventions. In recent years, many promising molecular and omic BOA have emerged with an enormous potential for translational geroscience and improving healthspan. However, clinical translation remains limited, in part due to the gap between preclinical research and the application of BOA in clinical research and other translational settings.
-
Aug 23, 2024 |
nature.com | Christine Yeh |Olivia Laveroni |Subin Kim |Aihui Wang |Brooke Liang |Raeline Valbuena | +4 more
AbstractThe drivers of immune evasion are not entirely clear, limiting the success of cancer immunotherapies. Here we applied single-cell spatial and perturbational transcriptomics to delineate immune evasion in high-grade serous tubo-ovarian cancer. To this end, we first mapped the spatial organization of high-grade serous tubo-ovarian cancer by profiling more than 2.5 million cells in situ in 130 tumors from 94 patients.
-
May 19, 2024 |
conservativefiringline.com | Michael Snyder
Once thousands of nanobots are zipping around inside your body, will you still be in control of your mind, will and emotions or will the nanobots be running the show? According to Google, a nanobot is “a hypothetical, very small, self-propelled machine, especially one that has some degree of autonomy and can reproduce”.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →